Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer

Oncotarget

Volumn 6, Issue 40, 2015, Pages 42396-42410

  Di Desidero, Teresa ^a,b   Xu, Ping ^a   Man, Shan ^a   Bocci, Guido ^b   Kerbel, Robert S ^a,c  

^a Canada   (Canada)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Metastatic triple negative breast cancer; Metronomic chemotherapy; Pazopanib; Topotecan

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PAZOPANIB; SUNITINIB; TOPOTECAN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL HYPOXIA; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PROLIFERATIVE INDEX; PROTEIN EXPRESSION; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE; MICE, SCID; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; SULFONAMIDES; TOPOTECAN; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84952303328     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6377     Document Type: Article

References (69)

1. Kerbel RS. (2014). Development and Evolution of the Concept of Metronomic Chemotherapy: A PersonalPerspective. In: Bocci G and Francia G, ed. Metronomic Chemotherapy Pharmacology and Clinical Applications: Springer, pp. 3-21.
2. Kerbel RS. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res Treat. 2007; 39:150-159.
3. Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli C, Goldhirsch A, Bertolini F and Colleoni M. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer. 2012; 12:207-214.
4. Young SD, Lafrenie RM and Clemons MJ. Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr Oncol. 2012; 19:e75-83.
5. Fedele P, Marino A, Orlando L, Schiavone P, Nacci A, Sponziello F, Rizzo P, Calvani N, Mazzoni E, Cinefra M and Cinieri S. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer. 2012; 48:24-29.
6. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E and Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008; 26:4899-4905.
7. Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer (SYSUCC-001). NCT01112826. http://clinicaltrials.gov/ct2/show/NCT01112826?term=metronomic+phase+III&rank=2.
8. Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC (CAMELLIA). NCT01917279. http://clinicaltrials.gov/ct2/show/NCT01917279?term=metronomic+phase+III&rank=1.
9. Montagna E, Cancello G, Dellapasqua S, Munzone E and Colleoni M. Metronomic therapy and breast cancer: a systematic review. Cancer Treat Rev. 2014; 40:942-950.
10. Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ and Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385: 1843-52.
11. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J and Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009; 8:1596-1603.
12. Hackl C, Man S, Francia G, Milsom C, Xu P and Kerbel RS. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. 2013; 62:259-271.
13. Aljuffali IA, Mock JN, Costyn LJ, Nguyen H, Nagy T, Cummings BS and Arnold RD. Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. Cancer Biol Ther. 2011; 12:407-420.
14. Minturn JE, Janss AJ, Fisher PG, Allen JC, Patti R, Phillips PC and Belasco JB. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer. 2011; 56:39-44.
15. Tillmanns TD, Stewart CF, MacEachern J, Schaiquevich P, Walker MS and Stepanski EJ. Daily oral topotecan: Utilization of a metronomic dosing schedule to treat recurrent or persistent solid tumors. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008; 26:suppl 2571.
16. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R and Kerbel RS. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther. 2010; 9:996-1006.
17. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R and Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010; 9:985-995.
18. Kumar S, Mokhtari RB, Sheikh R, Wu B, Zhang L, Xu P, Man S, Oliveira ID, Yeger H, Kerbel RS and Baruchel S. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011; 17:5656-5667.
19. Kumar S, Mokhtari RB, Oliveira ID, Islam S, Toledo SR, Yeger H and Baruchel S. Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts. Transl Oncol. 2013; 6:493-503.
20. Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, Bjarnason GA, Bocci G and Kerbel RS. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med. 2015 Apr 8;7:282ra50.
21. Turner DC, Tillmanns TD, Harstead KE, Throm SL and Stewart CF. Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer. Anticancer Res. 2013; 33:3823-3829.
22. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF and Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28:1061-1068.
23. Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer (PazoX). NCT01498458. http://clinicaltrials.gov/ct2/show/study/NCT01498458?term=pazopanib+breast&rank=2.
24. Treatment With Pazopanib for Neoadjuvant Breast Cancer. NCT00849472. http://clinicaltrials.gov/ct2/show/NCT00849472?term = pazopanib+breast&rank = 1.
25. Amiri-Kordestani L, Tan AR and Swain SM. Pazopanib for the treatment of breast cancer. Expert Opin Investig Drugs. 2012; 21:217-225.
26. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM and Pandite L. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009; 15:4220-4227.
27. Tan AR, Dowlati A, Jones SF, Infante JR, Nishioka J, Fang L, Hodge JP, Gainer SD, Arumugham T, Suttle AB, Dar MM, Lager JJ and Burris HA, 3rd. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist. 2010; 15:1253-1261.
28. Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard KI and Leighl NB. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist. 2010; 15:810-818.
29. Kumler I, Brunner N, Stenvang J, Balslev E and Nielsen DL. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2013; 138:347-358.
30. Andre F and Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012; 23 Suppl 6:vi46-51.
31. Sledge GW. Anti-vascular endothelial growth factor therapy in breast cancer: game over? J Clin Oncol. 2015; 33:133-135.
32. Rugo HS. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? J Clin Oncol. 2012; 30:898-901.
33. Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, Verma S, Collins LL, Paterson AH, Robidoux A and Pritchard KI. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev. 2012; 38:673-688.
34. Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U and Mustacchi G. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15:1351-1360.
35. Bear HD, Tang G, Rastogi P, Geyer CE, Jr., Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012; 366:310-320.
36. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012; 366:299-309.
37. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013; 14:933-942.
38. Bear HD, Tang G, Rastogi P, Geyer CE, Jr., Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015; 16:1037-1048.
39. Francia G, Cruz-Munoz W, Man S, Xu P and Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 2011; 11:135-141.
40. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G and Kerbel RS. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006; 66:3386-3391.
41. Guerin E, Man S, Xu P and Kerbel RS. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 2013; 73:2743-2748.
42. Paez-Ribes M, Man S, Xu P and Kerbel RS. Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. Clin Cancer Res. 2015, doi: 10.1158/1078-0432.CCR-15-0915.
43. Rovida A, Castiglioni V, Decio A, Scarlato V, Scanziani E, Giavazzi R and Cesca M. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice. Mol Cancer Ther. 2013; 12:2237-2247.
44. Alishekevitz D, Bril R, Loven D, Miller V, Voloshin T, Gingis-Velistki S, Fremder E, Scherer SJ and Shaked Y. Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing. Mol Cancer Ther. 2014; 13:202-213.
45. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357:2666-2676.
46. Burris H, Dowlati A, Gainer S, Park J, Stutts M, Dar M, Suttle B, Mitrica I and Tan AR. Pazopanib combination with paclitaxel and carboplatin in patients with advanced solid tumors and gynecological cancers: results of two phase I studies. Molr Cancer Ther. 2009; 8:Supplement 1(abstract A6).
47. Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, Goldhirsch A, D'Alessandro C, Cinieri S, Preda L and Colleoni M. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2006; 17:961-967.
48. Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P and Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med. 2014; 6:1561-1576.
49. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH and Melillo G. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009; 8:1867-1877.
50. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH and Melillo G. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004; 64:6845-6848.
51. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3:721-732.
52. Rapisarda A and Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol. 2012; 9:378-390.
53. Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P and Rottenberg S. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One. 2012; 7:e45248.
54. Krishnamurthy P and Schuetz JD. The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival. Biometals. 2005; 18:349-358.
55. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP and Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004; 279:24218-24225.
56. Shukla S, Robey RW, Bates SE and Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009; 37:359-365.
57. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6:789-802.
58. Canu B, Fioravanti A, Orlandi P, Di Desidero T, Ali G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R and Bocci G. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia. 2011; 13:217-229.
59. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW and Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol. 1992; 31:229-239.
60. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103:1656-1664.
61. Zhang FL, Wang P, Liu YH, Liu LB, Liu XB, Li Z and Xue YX. Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells. PLoS One. 2013; 8:e81815.
62. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011; 71:3364-3376.
63. Holliday DL and Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011; 13:215.
64. Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA and Kerbel RS. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res. 2009; 15:6358-6366.
65. Fioravanti A, Canu B, Ali G, Orlandi P, Allegrini G, Di Desidero T, Emmenegger U, Fontanini G, Danesi R, Del Tacca M, Falcone A and Bocci G. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Eur J Pharmacol. 2009; 619:8-14.
66. Cruz-Munoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, Collins C, Banville M, O'Connor-McCourt MD and Kerbel RS. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis. 2014; 17:661-673.
67. Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA and Stewart CF. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res. 2009; 69:5885-5892.
68. Hubbard KE, Schaiquevich P, Bai F, Fraga CH, Miller L, Panetta JC and Stewart CF. Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomed Chromatogr. 2009; 23:707-713.
69. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M and Allegrini G. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer. 2008; 98:1619-1629.